0001388320 false 0001388320 2023-11-30 2023-11-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 30, 2023 
 

ACTINIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

 

Delaware   001-36374   74-2963609
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

275 Madison Avenue, 7th Floor, New York, NY 10016

(Address of Principal Executive Offices)

 

Registrant’s telephone number: (646) 677-3870

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ATNM   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Election of Class I Directors

 

On November 30, 2023, Actinium Pharmaceuticals, Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “Annual Meeting”). As previously reported in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2023 (the “Proxy Statement”), the term of each of the Company’s Class I directors was scheduled to expire at the Annual Meeting, and the Company’s board of directors (the “Board”) nominated each director for re-election at the Annual Meeting.

 

At the Annual Meeting, each of David Nicholson and Richard I. Steinhart was elected as a Class I director of the Board to serve for a term expiring at the Company’s 2026 annual meeting of stockholders.

  

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

A total of 16,495,465 shares of the Company’s common stock were present in person or represented by proxy at the Annual Meeting. Holders of the Company’s common stock were entitled to one vote per share. The following two proposals were submitted to the Company’s stockholders at the Annual Meeting:

 

(1) To elect each of David Nicholson and Richard I. Steinhart as a Class I director to serve for a three-year term that expires at the 2026 Annual Meeting of Stockholders, or until his successor is elected and qualified or until his earlier resignation or removal:

 

Director   For   Withhold   Broker Non-Votes
David Nicholson   3,959,659   3,275,844   9,087,835
Richard I. Steinhart   5,630,379   1,777,251   9,087,835

 

(2) To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023:

 

For   Against   Abstain   Broker Non-Votes
15,842,146   372,774   280,545   N/A

 

For more information about the foregoing proposals, see the Proxy Statement, the relevant portions of which are incorporated herein by reference.

 

The results reported above are final voting results. No other matters were considered or voted upon at the meeting.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Actinium Pharmaceuticals, Inc.
   
Date: December 1, 2023 /s/ Sandesh Seth
  Name: Sandesh Seth
  Title: Chairman and Chief Executive Officer

 

2

 

 

v3.23.3
Cover
Nov. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 30, 2023
Entity File Number 001-36374
Entity Registrant Name ACTINIUM PHARMACEUTICALS, INC.
Entity Central Index Key 0001388320
Entity Tax Identification Number 74-2963609
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 275 Madison Avenue
Entity Address, Address Line Two 7th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 646
Local Phone Number 677-3870
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ATNM
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false

Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2024 à Fév 2024 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2023 à Fév 2024 Plus de graphiques de la Bourse Actinium Pharmaceuticals